Measured Wealth Private Client Group’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Measured Wealth Private Client Group’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-639	Closed	-$2K	–	225
2019 Q1	$2K	Buy	639 +50	+8%	+$147	﹤0.01%	175
2018 Q4	$1K	Sell	589 -50	-8%	-$206	﹤0.01%	104
2018 Q3	$2K	Hold	639	–	–	﹤0.01%	786
2018 Q2	$2K	Buy	+639	New	+$3.34K	﹤0.01%	139

Other funds holding NAVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

ACM

Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Measured Wealth Private Client Group's NAVB Position: Q2 2019 in Review

Measured Wealth Private Client Group sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2019, closing a stake of 639 shares — an estimated $2K sold.

Measured Wealth Private Client Group first reported a position in NAVB in Q2 2018 and held it in 4 quarters. The position peaked at $2K in Q1 2019. 27 funds tracked by Wall St. Rank hold NAVB as of Q2 2019.

Measured Wealth Private Client Group reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2019 after selling out during the quarter.
Measured Wealth Private Client Group sold 639 Navidea Biopharmaceuticals Inc. shares in Q2 2019, an estimated $2K.
Measured Wealth Private Client Group first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2018 and held it in 4 quarters.
Measured Wealth Private Client Group's Navidea Biopharmaceuticals Inc. position peaked at $2K in Q1 2019.
27 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2019.

Based on Measured Wealth Private Client Group's 13F filing for Q2 2019, filed 26 Jul 2019.